Aug. 12 at 11:56 AM
$SLS NO GPS talk! I'm only focused on what wallstreet MISSED - the Pancreatic BOMB 💣 thus officially expanding their game plan into solid cancers!
$195 easily!
$RVMD sits at a RIDICULOUS
$44B market cap after a Phase 3 trial that ONLY extended life by a few months ( 13.2 vs. 6.7 months for chemo with an HR of 0.40).
NOW
$SLS is aiming straight at
$RVMD +pulling off absolute madness:
Pancreatic (PDAC): SLS009 CRUSHED RAS-resistant pancreatic cancer cells where standard inhibitors fail YEP we talking about
$RVMD -While RVMD relies heavily on RAS inhibition,
$SLS has the weapon to conquer the exact resistance mechanisms
$RVMD's drug can't touch!
REGAL Trial: 47 patients still living 29 months post-enrollment, while we sit waiting on a single death to drop an absurd .02 or .03 HR.
RVMD has no revenue and identical shares, yet commands a
$44B valuation.
50% of
$RVMD (
$22B cap):
$SLS $97 per share
100% match
$RVMD (
$44B cap)
$SLS $195+ per share
NO-brainer setup. SEE YA SOON
$LLY $JNJ $MRK
